我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
14
13 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
13
92.9%
招募中
1
7.1%
暂无批准数据
- ViiV Healthcare presented extensive real-world data at IAS 2025 demonstrating the effectiveness, safety, and tolerability of its long-acting injectable HIV treatments, including cabotegravir + rilpivirine LA for treatment and cabotegravir LA for prevention. - The phase IIIb VOLITION study revealed strong patient preference for switching to long-acting injectables after achieving rapid viral suppression with daily oral therapy, highlighting the appeal of reduced dosing frequency. - Multiple real-world studies including COMBINE-2, CARLOS, BEYOND, and OPERA cohort provided 24-month outcomes data showing sustained effectiveness and high patient satisfaction with the long-acting regimen across diverse populations. - Implementation studies PILLAR and EBONI demonstrated positive experiences with cabotegravir long-acting for PrEP among men who have sex with men, transgender men, and Black women, supporting broader adoption of injectable prevention strategies.
